How safe is Celecoxib for Asian–Indian patients with rheumatic diseases?

Danda, Debashish; Iliyas, Mohamed M.; Chandy, Sujith J; Chandra, Cheemalapati; Mathew, Ashish Jacob

doi:10.1111/1756-185x.12043

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, while the previously mentioned patient-level meta-analysis by White et al concluded that there is no difference in incidence of cardiovascular events between Celecoxib and non-selective NSAIDs, several points in the clinical trials do not match our study criteria ( 21 , 57 ). First of all, the majority of these trials were <26 weeks in duration, offering limited insights.…”

Section: Discussionmentioning

confidence: 60%

Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: A nationwide retrospective cohort study

Chen

Lee²,

Perng³

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

Background and purposePrevious studies reported conflicting results about the risk of ischemic stroke associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with rheumatoid arthritis (RA). We aimed to investigate two specific COX-2 inhibitors, Celecoxib and Etoricoxib, and their corresponding effects on the risk of ischemic stroke in patients with RA.Patients and methods10,857 patients newly diagnosed with RA were identified and sampled from the Taiwanese National Health Insurance Research Database during the period from 2001 to 2009. The identification of RA was based on the criteria of ICD-9-CM diagnosis code 714.0. Patients diagnosed with cerebrovascular disease and those receiving RA treatment prior to the first diagnosis of RA were excluded. Study endpoint was ischemic stroke, defined by ICD-9-CM code. Cox proportional hazard models and Kaplan Meier curves were used to reveal covariates and differences by drugs in the risk of ischemic stroke. Dosages for Celecoxib were defined as ≤ 200 and >200 mg/day; those for Etoricoxib were 0 and >0 mg/day.ResultsAmong 7,904 RA patients, 6,669 did not take Celecoxib and 564 (8.46%) of them experienced an ischemic stroke event. Of the 597 individuals who took ≤ 200 mg/day of Celecoxib, 58 (9.72%) had strokes. Of the 638 patients who took >200 mg/day of Celecoxib, 38 (5.96%) eventually experienced a stroke. Among the 7,681 patients who did not take Etoricoxib, 654 (8.51%) experienced an ischemic stroke, while 6 (2.69%) in 223 patients who consumed Etoricoxib had a stroke event. Consuming more than 200 mg of Celecoxib per day for <3.5 years lowered the incidence rate for strokes [hazard ratio (HR) 0.67, 95% Confidence Interval (CI) 0.48–0.93 for dosage and HR 0.22, 95% CI 0.10–0.46 for duration, both p < 0.001], while consuming any dosage of Etoricoxib significantly decreases the possibility (HR 0.35, 95% CI 0.16–0.80, p < 0.001). On the other hand, consuming Etoricoxib for 8 years might have a neutral or even a potentially protective effect compared to at 3.8 years.ConclusionThis population-based retrospective cohort study has shown that Celecoxib and Etoricoxib reduce the risk of ischemic stroke in patients with RA in a dose- and time-dependent manner.

show abstract

Section: Discussionmentioning

confidence: 60%

Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: A nationwide retrospective cohort study

Chen

Lee²,

Perng³

et al. 2022

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…These paradoxical results of Celecoxib being protective at a higher dose in a shorter duration but harmful in a longer duration, as well as the neutral to slight protective effects of Etoricoxib, require further investigation to understand their underlying physiological mechanisms. Clinical trials mentioned in a patient-level meta-analysis concluded that there was no difference in the incidence of cardiovascular events between Celecoxib and non-selective NSAIDs [ 137 , 154 ]. Additional clinical trials may be necessary to establish causality rather than just an association between NSAID use and the risk of ischemic stroke.…”

Section: The Association Between Nsaids and Risk Of Ischemic Stroke: ...mentioning

confidence: 99%

Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care

Al-Ewaidat,

Naffaa

2024

Clin Exp Med

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) can independently increase the risk of stroke, affecting both young and adult RA patients. Recent attention has been drawn to the association between stroke and RA, supported by mounting evidence. Given that stroke is a significant and an urgent public health concern, this review aims to highlight the relationship between stroke and RA, covering mechanisms, underlying risk factors, early detection tools, and treatment implications. By uncovering the connection that links RA to stroke, we can pave the way for targeted healthcare practices and the development of preventive strategies for individuals with RA. Therefore, further research is imperative to deepen our understanding of this association and, ideally, guide treatment decisions for individuals at risk of both RA and stroke.

show abstract

“…Celecoxib ( Figure 1 ), a selective cyclooxygenase-2 (COX-2) inhibitor, has been widely used to treat arthritis for many years [ 1 , 2 ]. Recently, it was reported to be useful against breast cancers as an adjuvant drug [ 3 – 6 ].…”

Section: Introductionmentioning

confidence: 99%

Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS

Xiang

Wen

Liu

et al. 2017

Biochemistry Research International

View full text Add to dashboard Cite

Objective To discuss the effects of genistein on the metabolism of celecoxib in vitro and in vivo. Method In vitro, the effects of genistein on the metabolism of celecoxib were studied using rat and human liver microsomes. In vivo, pharmacokinetics of celecoxib was evaluated in rats with or without genistein. Fifteen Sprague-Dawley (SD) rats were randomized into three groups: celecoxib (A group), celecoxib and 50 mg/kg genistein (B group), and celecoxib and 100 mg/kg genistein (C group). Single dose of 33.3 mg/kg celecoxib was orally administered 30 min after genistein ig. At 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after celecoxib administration, 300–400 µl blood samples were collected and the concentration of celecoxib was analyzed by ultrahigh-performance liquid chromatography-tandem mass spectrometry system. Result Genistein showed notable inhibitory effects on three microsomes. It affected pharmacokinetics of celecoxib in vivo experiments. Genistein had dramatically ability to suppress CYP2C9∗1 and ∗3. After pretreatment with genistein, AUC and Cmax of the C group were higher than B group. CLz/F of C group was lower than the B group. Conclusion Genistein inhibits the conversion of celecoxib in vitro and in vivo. So, the dosage of celecoxib should be adjusted if it was used associated with genistein.

show abstract

How safe is Celecoxib for Asian–Indian patients with rheumatic diseases?

Abstract: Background: Cyclo-oxygenase (COX)-2 inhibitors have been the target of severe criticism, more so following the withdrawal of Rofecoxib. Post-marketing surveillance of Celecoxib in Asian Indians, who are predisposed to premature athero-thrombotic events, has not been studied.

Cited by 3 publications

References 20 publications

Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: A nationwide retrospective cohort study

Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: A nationwide retrospective cohort study

Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care

Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS

Contact Info

Product

Resources

About